IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
Novo Nordisk semaglutide trial clears obesity in 40% of young children
Novo Nordisk announced positive top-line results from its STEP Young phase 3 trial evaluating semaglutide in children aged 6 to under 12 with...
🟢 Health ETF (IYH) is trading 5.2% up in pre-market amid optimism over AstraZeneca’s Etcamah approval
IYH is trading at $76.18, up 5.22% before the September 8, 2026 open, amid optimism over AstraZeneca’s FDA accelerated approval of Etcamah. - Etcamah is an...
AstraZeneca Wins FDA Approval for Etcamah, a First for Liquid Biopsies
The FDA granted accelerated approval to AstraZeneca’s camizestrant, marketed under the brand name Etcamah. The therapy treats adult patients with HR-positive,...
Eli Lilly buys Merida for $2.88B, diversifying beyond blockbuster obesity drugs
Eli Lilly will acquire Merida Biosciences in an all-cash deal valued at up to $2.88 billion. This transaction marks the pharmaceutical giant’s 13th acquisition...
Pfizer, BioNTech Win FDA Approval for Updated COVID Vaccine, Targeting XFG
The U.S. Food and Drug Administration (FDA) approved Pfizer and BioNTech’s supplemental Biologics License Application for an updated COVID-19 vaccine. This new...
Eli Lilly buys Merida Biosciences for $2.875B, expanding into autoimmune therapies
Eli Lilly and Company signed a definitive agreement to acquire Merida Biosciences. The deal is valued at up to $2.875 billion. This total includes an upfront...
TRIC-I-HF Trial Slashes Death Risk for Severe Tricuspid Regurgitation Patients
The TRIC-I-HF trial results presented at the European Society of Cardiology (ESC) Congress 2026 show transcatheter tricuspid valve repair improves outcomes for...
TRIC-I-HF Trial Cuts Heart Failure Deaths, Improving Three-Year Patient Survival
The TRIC-I-HF trial results presented at the European Society of Cardiology (ESC) Congress 2026 show transcatheter tricuspid valve repair improves high-risk...
Eli Lilly’s Mounjaro wins FDA heart approval, boosting blockbuster market lead
The FDA approved an expanded indication for Eli Lilly’s Mounjaro to reduce the risk of major adverse cardiovascular events (MACE). This approval applies to...
🟢 Health ETF (IYH) is trading 5.9% up in pre-market after FDA approval for Mounjaro’s cardiovascular-risk reduction
IYH is trading at $76.90 (+5.88%) in pre-market after Eli Lilly received FDA approval for Mounjaro to reduce cardiovascular-event risk. - The approval...
Revolution Medicines wins FDA approval, doubling survival in pancreatic cancer patients
The U.S. Food and Drug Administration granted expedited approval to Revolution Medicines' new drug, daraxonrasib (brand name: Rasonque). This first-of-its-kind...
Quest Diagnostics to Offer First FDA-Cleared Alzheimer's Blood Test, Replacing Invasive Scans
Quest Diagnostics will begin offering Roche's Elecsys Phospho-Tau (217P) Plasma (pTau217) assay. This is the first and only FDA-cleared blood test designed to...
🔴 Health ETF (IYH) is trading 3% down in pre-market on August 24, 2026 amid risk aversion
IYH is trading at $71.67, down 3.00% from the August 21 close amid global risk aversion. - U.S. futures and technology lower; elevated long-term Treasury...
J&J Secures EU Approval for TECVAYLI as Second-Line Myeloma Therapy
Johnson & Johnson received European Commission approval for an expanded indication of its cancer drug TECVAYLI (teclistamab). The approval authorizes the...
🟢 Health ETF (IYH) is trading 3.32% up in pre-market on Trump’s nomination of Dr. Heidi Overton
IYH is trading at $75.40 (+3.32%), driven by President Trump’s nomination of Dr. Heidi Overton to lead the FDA. - The nomination could end the agency’s...
Trump Nominates Dr. Heidi Overton for FDA, Signaling Vaccine Policy Shift
President Donald Trump nominated Dr. Heidi Overton to lead the Food and Drug Administration. Dr. Overton currently serves as a White House health policy aide...
Moderna, Merck shares surge on successful Phase 3 cancer vaccine trial
Merck and Moderna announced that their individualized neoantigen therapy, intismeran, met its primary endpoint in a Phase 3 melanoma trial. The combination of...
🟢 Health ETF (IYH) is trading 3.29% up today on melanoma-vaccine optimism
IYH is trading 3.29% up today as healthcare benefits from investor rotation away from technology amid elevated Treasury yields, geopolitical uncertainty, and...
BioMarin buys Alesta for $275M, targeting first oral rare bone drug
BioMarin Pharmaceutical signed a definitive agreement to acquire clinical-stage biotech Alesta Therapeutics. The deal centers on ALE1, an oral small molecule...
Bristol-Myers Squibb Wins FDA Approval for Iberdomide, Using Landmark Cancer Endpoint
The FDA approved Bristol-Myers Squibb’s iberdomide combination therapy for adults with relapsed or refractory multiple myeloma. This regimen combines...